HRCM
BBIO icon

Hood River Capital Management’s BridgeBio Pharma BBIO Stock Holding History

Hood River Capital Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$93.9M Buy
1,265,080
+9,895
+0.8% +$717K 0.94% 36
2025
Q4 		$96M Buy
1,255,185
+11,640
+0.9% +$764K 1.05% 31
2025
Q3 		$64.6M Buy
+1,243,545
New +$60.7M 0.76% 50

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hood River Capital Management's BBIO Position: Q1 2026 in Review

Hood River Capital Management increased its BridgeBio Pharma (BBIO) stake by 0.79% in Q1 2026, buying an estimated $717K and bringing the position to 1,265,080 shares worth $93.9M. The position accounts for 0.94% of the portfolio, ranked #36.

Hood River Capital Management first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $96M in Q4 2025. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Hood River Capital Management held 1,265,080 shares of BridgeBio Pharma worth $93.9M as of Q1 2026.
  • Hood River Capital Management bought 9,895 BridgeBio Pharma shares in Q1 2026, an estimated $717K.
  • BridgeBio Pharma made up 0.94% of Hood River Capital Management's portfolio in Q1 2026, its #36 holding.
  • Hood River Capital Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • Hood River Capital Management's BridgeBio Pharma position peaked at $96M in Q4 2025.
  • 457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Hood River Capital Management's 13F filing for Q1 2026, filed 15 May 2026.